Randomized comparison of the cost and effectiveness of iopamidol and diatrizoate as contrast agents for cardiac angiography.
To evaluate the effectiveness and cost of low osmolarity, nonionic contrast agents for cardiac angiography, 443 patients were randomized to receive either iopamidol or diatrizoate. All adverse events that occurred within 24 h of the procedure were recorded prospectively by study personnel and classified according to previously determined criteria. Major events were defined as life threatening or requiring a procedure to treat, or both. Costs of the catheterization procedure, pharmacy, hospital laboratory and treatment of adverse events were determined on the basis of actual resource use. A total of 20 patients (8.5%) had major and 143 (61%) had minor adverse events with diatrizoate use; 10 patients (4.8%) had major and 53 (25%) had minor adverse events with iopamidol (p = 0.12 for major events; p less than 0.001 for total events). Most adverse events were treated fairly easily and inexpensively. The median overall cost was $186 higher for patients after iopamidol use compared with diatrizoate (p less than 0.0001), but all costs except the cost of the contrast agent were not significantly different between the two groups. Thus, patients who received iopamidol for cardiac angiography had a significantly lower rate of adverse events than those who received diatrizoate, but this difference was achieved at a considerably high overall cost.
Hlatky
M A
MA
Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Morris
K G
KG
Pieper
K S
KS
Davidson
C J
CJ
Schwab
S J
SJ
Bashore
T M
TM
D000790:Angiocardiography / Q000191:economics*; D006328:Cardiac Catheterization / Q000191:economics; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D003973:Diatrizoate / Q000009:adverse effects; D005260:Female; D006801:Humans; D007479:Iopamidol / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
D003973:Diatrizoate; D007479:Iopamidol